Protalix BioTherapeutics (PLX) Reports Q4 Loss of $0.29/Share
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.73 +2.25%
Revenue Growth %: -15.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -15.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.29), versus ($0.36) reported last year. Revenue for the quarter came in at $4.4 million, versus $3.5 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Adobe beats Q3 targets, but soft Q4 sales guidance triggers dip
- Cosciens acquires Nualtis for up to $15M in cash deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
